Valuation: Lucy Scientific Discovery Inc.

Market Cap 907K 810K 748K 678K 1.27M 86.09M 1.29M 9M 3.56M 45.11M 3.4M 3.33M 142M P/E 2022 *
-
P/E 2023 -1.63x
Enterprise Value 1.02M 912K 843K 764K 1.43M 97M 1.45M 10.14M 4.02M 50.82M 3.83M 3.75M 160M EV / Sales 2022 *
-
EV / Sales 2023 2,682,682,605x
Free-Float
81.97%
Yield 2022 *
-
Yield 2023 -
1 month 0
Extreme 0.0001
0
Current year 0
Extreme 1.0E-5
0
1 year 0
Extreme 1.0E-5
0.01
3 years 0
Extreme 1.0E-6
4.1
5 years 0
Extreme 1.0E-6
40
10 years 0
Extreme 1.0E-6
40
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 75 2021-01-31
Date Insider Type Main position Quantity % Market Cap. Importance
2/13/23 Others

Chief Technology Officer

85,000 -
2/13/23 Others

Chief Executive Officer

984,590 -
2/13/23 Others

Director

9,309 -
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-66.67%-100.00% 176
-2.54%+1.31%+54.27%+117.14% 1,135B
-1.42%+3.23%+38.56%+74.05% 635B
+0.16%+0.08%+25.29%+96.64% 505B
-0.31%+3.09%+44.14%+64.55% 378B
-1.34%-0.47%+66.04%+40.18% 358B
-0.68%+2.65%+22.98%+49.15% 295B
-1.20%+3.04%+2.33%+21.60% 266B
-1.79%+1.57%+50.56%+61.40% 237B
-0.73%-0.10%+29.02%+99.06% 193B
Average -0.98%+1.44%+26.65%+52.38% 400.37B
Weighted average by Cap. -1.35%+1.63%+41.02%+80.33%

Financials

2022 2023
Net sales - 0.01 0.01 0.01 0.01 0.01 0.67 0.01 0.07 0.03 0.35 0.03 0.03 1.11
Net income -5.86M -5.23M -4.83M -4.38M -8.19M -556M -8.33M -58.14M -23.02M -291M -21.98M -21.51M -918M -8.99M -8.03M -7.42M -6.72M -12.57M -853M -12.78M -89.23M -35.33M -447M -33.73M -33.02M -1.41B
Net Debt 4.77M 4.26M 3.93M 3.56M 6.67M 452M 6.78M 47.32M 18.73M 237M 17.89M 17.51M 747M 115K 103K 94.81K 85.92K 161K 10.91M 163K 1.14M 452K 5.72M 431K 422K 18.02M
Logo Lucy Scientific Discovery Inc.
Lucy Scientific Discovery Inc. is an early stage psychotropics contract manufacturing company. The Company is engaged in researching, developing, and manufacturing psychotropic drugs. The Company is a manufacturer of controlled compounds dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic and psychedelic treatment therapies. It is focused on developing therapies for patients in need, and through its lead candidate SANA-013, dedicated to advancing the understanding and applications of psychedelic medicine, improving mental health outcomes, and enhancing well-being for individuals worldwide. The Company is engaged in the production of a variety of natural, synthetic, and biosynthetic products to meet the needs of the psychotropics-based medicines market. Its products are in the form of raw materials, crude extracts, targeted formulations, single molecule fractions, and white- and private-label products.
Employees
-

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Lucy Scientific Discovery Inc.
  1. Stock Market
  2. Stocks
  3. LSDIF Stock